Month: February 2023

BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows. A MESSAGE FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER To my fellow stockholders, We look forward to 2023 after a challenging 2022 when small biotechnology companies endured one of their worst years on record. First Wave BioPharma was not immune to this unfortunate trend, but we weathered the storm. We look forward...

NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $10 million non-dilutive milestone payment under its collaboration agreement with Roche to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers. The success-based milestone payment reflects the start of the HB-700 manufacturing process to support a Phase 1 clinical trial. HOOKIPA plans to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration in the first half of 2024. “We’re really pleased to start the year strongly by achieving this milestone in our collaboration with Roche to develop HB-700 for KRAS-mutated cancers,” said Joern...

STRASBURG, Va., Feb. 13, 2023 (GLOBE NEWSWIRE) — The Board of Directors of First National Corporation (Nasdaq: FXNC) declared a quarterly cash dividend of $0.15 per share on February 8, 2023. This was a 7% increase compared to the quarterly dividend paid on December 16, 2022. The dividend is payable on March 10, 2023, to shareholders of record as of February 24, 2023. ABOUT FIRST NATIONAL CORPORATION First National Corporation (NASDAQ: FXNC) is the parent company and bank holding company of First Bank, a community bank that first opened for business in 1907 in Strasburg, Virginia. The Bank offers loan and deposit products and services through its website, fbvirginia.com, its mobile banking platform, a network of ATMs located throughout its market area, a loan production office, two customer service centers in retirement communities,...

VANCOUVER, British Columbia and ALISO VIEJO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — PowerTap Hydrogen Capital Corp. (NEO: MOVE) (OTC: MOTNF) (“PowerTap” or the “Company” or “MOVE”) provides an update on the activities of PowerTap and its subsidiary, PowerTap Hydrogen Fueling Corp. Further to the Company’s press release on November 23, 2022, PowerTap Hydrogen Fueling Corp., in conjunction with T2M Global, PowerTap’s technology partner, have further progressed the engineering and supply chain validation of the PowerTap Gen3 Modular Hydrogen Production and Dispensing Unit (MHPDU) in PowerTap’s plan to establish light-duty and heavy-duty fuel cell electric vehicle (FCEV) hydrogen (H2) refueling stations by 2024. As part of T2M Global’s progress on supply chain and technology validation of PowerTap’s Gen3 unit, T2M has...

Moody’s Investors Service (“Moody’s”) has today placed Kvika Banki hf.’s (“Kvika”) deposit and issuer ratings on review for upgrade as merger discussions with Íslandsbanki hf. commence. Given the review for upgrade, Moody’s is unlikely to downgrade Kvika’s ratings during the review period. However, failure to proceed with the merger would result into Kvika’s ratings to be confirmed at current levels provided that the bank continues to exhibit resilient financial performance. The review is placed on Kvika’s long-term deposit ratings of Baa1 and issuer ratings of Baa2. Furthermore, Moody’s also placed the bank’s Baseline Credit Assessment (BCA) and Adjusted BCA of ba1, the long-term Counterparty Risk (CR) Assessment of Baa1(cr) and Counterparty Risk Ratings (CRRs) of Baa1 on review for upgrade. The outlook on the long-term deposit and issuer...